Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by Phillip Bradley ordered by Published Date Descending.
Links to Result pages
What You Need To Know About Retained Rights In Federally Funded Patented Drugs
More than 50 members of Congress, led by Rep. Lloyd Doggett (D-TX), sent a letter to Secretary of Health and Human Services Sylvia Matthews Burwell and to National Institutes of Health (NIH) Director Francis Collins on January 11, 2016, urging the agencies "to utilize your existing statutory authority to respond to the soaring cost of pharmaceuticals" to address "price gouging" by pharmaceutical manufacturers
United States
1 Apr 2016
Many Questions For, But Not Many Answers From, The FDA On Biosimilars Implementation After Last Week's Hearing
The US Senate Committee on Health, Education, Labor and Pensions on September 17, 2015 convened a hearing entitled Biosimilars Implementation: A Progress Report from the FDA. Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research of the FDA appeared as the witness for the agency.
United States
2 Oct 2015
Identifying The Likely Beneficiaries Of An Emerging Biosimilars Market
Financial analysts have predicted that over the next five years, biosimilars will be a $10 billion market, so it is understandable why considerable attention and investment is being made in this space.
United States
3 Aug 2015
Patients' Voices Carry: Drug Development Increasingly Driven By Patients' Needs And Concerns
This client alert is the second of a three-part series that discusses hot topics to come out of the 2015 BIO International Convention.
United States
24 Jul 2015
Links to Result pages